Amazon Biotech to study AMZ0026's ability to delay onset of AIDS

By Angela McDaniels

Seattle, March 28 - Amazon Biotech Inc. said it is designing a protocol to test its AMZ0026 compound as an HIV drug used to delay the onset of AIDS.

The six-month study is designed to compare AMZ0026 with a placebo and will include 60 non-symptomatic HIV-infected subjects who have not been recently treated with any AIDS medications.

The primary endpoint parameters will include any increase in T cells and the number of HIV viruses in the bloodstream, according to a company news release.

Amazon Biotech said it will soon submit the protocol to the Food and Drug Administration as part of an existing Investigational New Drug application and will also hold a parallel study that will include symptomatic AIDS patients.

Amazon Biotech is a natural plant pharmaceutical company based in New York that develops primarily immune modulator drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.